update on imgn632: cd123 antibody-drug conjugate for r/r aml and bpdcn
Published 4 years ago • 194 plays • Length 5:18Download video MP4
Download video MP3
Similar videos
-
1:36
imgn632: a novel cd123-targeted antibody-drug conjugate for r/r bpdcn
-
3:45
imgn632: a novel cd123 adc for r/r aml and bpdcn
-
1:40
the promise of cd123-directed immunotherapy in aml and agents of interest
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
2:41
the potential of targeting cd123 in myeloid malignancies
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
1:24
phase i study of cd123 nk cell engager sar443579 in r/r aml, b-all or hr-mds
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:29
the current landscape of immunotherapy for aml: an update from ash 2023
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
2:03
evaluating germline variant gfi1-36n and its impact on dna repair in aml
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:49
what is scim? | identity-360